Climb Bio, Inc.

NASDAQ•CLYM

CEO: Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc

セクター: Healthcare

業種: Biotechnology

上場日: 2021-08-10

Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.

連絡先情報

PMB #117, 2801 Centerville Road, 1st Floor, Wilmington, DE, 19808-1609, United States

866-857-2596

eliemtx.com

時価総額

$499.79M

PER (TTM)

-8.3

17.4

配当利回り

52週高値

$8.04

52週安値

$1.05

52週レンジ

90%

順位49Top 66.7%

3.2

F-Score

改良版 Piotroski 分析

6年ファンダメンタル

弱い • 3.2 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2020-2025

財務ダッシュボード

Q4 2025 データ

売上高

$0.00+0.00%

直近4四半期の推移

EPS

-$0.26+0.00%

直近4四半期の推移

フリーCF

-$15.64M+0.00%

直近4四半期の推移

2025 Annual 決算ハイライト

主なハイライト

Net Loss Narrows Net loss narrowed to $(59.851M) USD in 2025 from $(73.897M) USD in 2024, showing operational improvement.

R&D Investment Surge Research and development expenses rose $32.377M to $46.713M USD, driven by advancement of budoprutug programs.

Strong Liquidity Position Cash and marketable securities totaled $160.744M USD as of December 31, 2025, funding operations into 2028.

リスク要因

Future Capital Needs Expect continued operating losses; substantial future financing required to fund development and potential commercialization efforts.

Development Uncertainty Clinical development is lengthy, complex, and expensive; success is not guaranteed for product candidates like budoprutug.

Internal Control Weaknesses Material weaknesses in internal control over financial reporting remain unremediated as of December 31, 2025, impacting timely reporting.

見通し

Budoprutug pMN Data Expected Anticipate reporting initial data from the low dose cohort of the PrisMN Phase 2 trial in the second half of 2026.

SC Formulation Data Coming Plan to share initial data from the Phase 1 clinical trial of the subcutaneous formulation in the first half of 2026.

CLYM116 Phase 1 Results Expect initial data from the CLYM116 Phase 1 trial in mid-2026 to support advancement into IgA Nephropathy patients.

同業比較

売上高 (TTM)

AGEN

$106.83M

-33.4%

SPRO

$35.77M

-64.7%

SEER

$16.58M

+18.2%

粗利益率 (最新四半期)

SPRO

100.0%

+0.0pp

OVID

87.1%

-12.9pp

SEER

52.0%

+4.3pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
CLYM	$499.79M	-8.3	-33.4%	0.3%
CNTX	$291.26M	-11.4	-30.9%	0.2%
ABOS	$204.13M	-1.5	-97.4%	21.7%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

N/M

売上高の変動が大きい

4四半期純利益CAGR

N/M

収益構造の変化

キャッシュフロー安定性

キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年3月24日

EPS:-$0.20

売上高:-

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし